Drug Profile

LB 2

Alternative Names: LB 201 - Centessa Pharmaceuticals; LB-2

Latest Information Update: 26 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lockbody
Class Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; B7-H1 antigen inhibitors; Cytotoxic T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

24 Jun 2026 Centessa Pharmaceuticals has been acquired by Eli Lilly and Company
28 Aug 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
30 Mar 2022 Centessa Pharmaceuticals plans to file IND for Solid tumours in 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com